B. Riley Issues Pessimistic Estimate for Lantheus Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Investment analysts at B. Riley lowered their Q3 2025 earnings per share (EPS) estimates for Lantheus in a research report issued to clients and investors on Thursday, March 20th. B. Riley analyst Y. Zhi now anticipates that the medical equipment provider will earn $1.51 per share for the quarter, down from their prior estimate of $1.57. B. Riley has a “Buy” rating and a $122.00 price objective on the stock. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million.

Other research analysts also recently issued research reports about the stock. Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.43.

Lantheus Stock Up 1.8 %

LNTH opened at $99.44 on Monday. The firm’s fifty day simple moving average is $92.77 and its two-hundred day simple moving average is $96.47. Lantheus has a 52-week low of $57.92 and a 52-week high of $126.89. The company has a market cap of $6.81 billion, a price-to-earnings ratio of 16.55 and a beta of 0.38.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 in the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its position in Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider’s stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Lantheus by 79.9% in the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider’s stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Lantheus by 40.5% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Lantheus during the 4th quarter worth $36,183,000. Finally, Groupama Asset Managment acquired a new stake in shares of Lantheus during the 3rd quarter worth about $439,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.